BridgeBio Oncology Therapeutics, Inc. BBOT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.80M | 28.50M | 24.62M | 21.63M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.96M | 168.86M | 145.82M | 124.29M | -- |
| Operating Income | -198.96M | -168.86M | -145.82M | -124.29M | -- |
| Income Before Tax | -182.11M | -154.10M | -134.04M | -114.93M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -182.11 | -154.10 | -134.04 | -114.93 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -182.11M | -154.10M | -134.04M | -114.93M | -- |
| EBIT | -198.96M | -168.86M | -145.82M | -124.29M | -- |
| EBITDA | -198.65M | -168.56M | -145.54M | -124.04M | -- |
| EPS Basic | -2.75 | -568.50 | -622.20 | -1.69K | -- |
| Normalized Basic EPS | -1.72 | -355.31 | -388.87 | -1.06K | -- |
| EPS Diluted | -2.75 | -568.50 | -622.20 | -1.69K | -- |
| Normalized Diluted EPS | -1.72 | -355.31 | -388.87 | -1.06K | -- |
| Average Basic Shares Outstanding | 283.56M | 203.56M | 123.94M | 43.97M | -- |
| Average Diluted Shares Outstanding | 283.56M | 203.56M | 123.94M | 43.97M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |